摘要
为探讨肾舒Ⅱ号(主药:生黄芪、当归、川芎、赤芍药、红花 )治疗肾病综合证 (NS)的疗效和机理,Wistar按Bertani法造模后,分别给予肾舒Ⅱ号、肾舒Ⅱ号+激素、激素+潘生丁治疗,连续 3周。观察各组大鼠生存质量、生存率、血浆蛋白、肾功能、GMP-140、D 二聚体,以及肾组织病理的变化。结果:肾舒Ⅱ号能降低NS模型鼠 24h尿蛋白量、升高模型鼠TP、ALB,降低模型鼠TG、CHOL,和GMP-140、D 二聚体含量,改善模型鼠肾组织变化,减轻肾小球细胞足突的融合;肾舒Ⅱ号+激素的疗效,优于单用肾舒Ⅱ号者,并与潘生丁合用激素的疗效相似。提示:该药对NS有较好的疗效,而减轻肾组织的病理变化是其可能的作用机理之一。
To observe the clinical effects of “Shenshu-Ⅱ” in treating nephrotic syndrome and explore its mechanism, Wistar rats were modeled by Bertani method and then treated respectively by “Shenshu-Ⅱ”, “Shenshu-Ⅱ” plus hormone, “Shenshu-Ⅱ” plus Persantine. The life quality, survival rate, plasma protein, kidney function, GMP-140, D-dimer and kidney tissues of rats in all groups were observed. Results: “Shenshu-Ⅱ” could decrease 24h urinary protein, increase TP, ALB, and reduce TG, CHOL, GMP-140 and D-dimer, improve kidney issues, relieve the fusion of glomerular cell process; “Shenshu-Ⅱ” plus hormone was better than simple “Shenshu-Ⅱ”, but similar to “Shenshu-Ⅱ” plus Persantine in above effects. It is demonstrated that “Shenshu-Ⅱ” can treat nephrotic syndrome possibly by relieving pathological changes of kidney tissues.
出处
《上海中医药杂志》
北大核心
2005年第2期49-52,共4页
Shanghai Journal of Traditional Chinese Medicine
关键词
肾病综合证
大鼠模型
肾舒Ⅱ号
Nephrotic syndrome
rat model
“Shenshu-Ⅱ”
kidney pathology
